Related to Celtic Pledges $50M to Establish Business to Develop Antibody-Drug Conjugates

• Viral Genetics Forms Anticancer Subsidiary to Exploit Metabolic Disruption Technology
  
• Rosetta Genomics Taps Warnex as Canadian Distributor for Cancer Diagnostics
  
• Facet Biotech Steps Up to Help Trubion Advance Early-Stage Anticancer Agent with a $20M Fee
  
• Scientists Uncover Molecular Pathway that Makes Tumors More Aggressive
  
• BioMarker Strategies Secures $1.7M to Expedite Live Tumor Cell Testing System
  
• Access Pharma Taps Accupac to Manufacture Oral Mucositis Therapy in North America
  
• Karus Taps Queen Mary, University of London's Expertise for PI3K Inhibitor Development
  
• Altor Scores $3M NCI Grant for Clinical Development of IL-2 Boosting Drug
  
• Roche Sequence Capture and Genome Sequencing Technologies to Be Evaluated for Cancer Genetics
  
• Sanofi-Aventis Gains License to Phase I Anticancer Agent from Merrimack for $60M Up Front
  
• Researchers Link Anticancer Activity of Actinomycin D with NEDDylation Inhibition
  
• YM BioSciences to Take Over Cytopia Gaining Base in Australia
  
• Transgenomic Licenses Cold-PCR Technology from the Dana-Farber Cancer Institute
  
• TargetEx Takes Over Coordinating European CancerGrid Project
  
• Serametrix Allies with Ludwig Institute to Exploit Tumor Antigens as Biomarkers
  
• BioTime Sets Up Subsidiary to Develop hESC-Based Therapies for Cancer
  
• Genetic Tech to Distribute Rosetta’s Cancer Tests in Australia, New Zealand, and Singapore
  
• GE and Lilly Develop Prototype to Visualize and Map Cancer Biomarker Networks
  
• Bayer Decides to Investigate Compugen’s Newly Discover Cancer Targets
  
• Sangretech Gives Bostwick Scientific Rights to Its Dendritic-Cell Technology